www.idosr.org Namirimu, 2025

©IDOSR PUBLICATIONS

ISSN: 2550-7931

International Digital Organization for Scientific Research IDOSRJAS1020000
IDOSR JOURNAL OF APPLIED SCIENCES 10(2):53-58, 2025.
https://doi.org/10.59298/IDOSRJAS/2025/102.5358

CRISPR-Based Gene Editing Approaches for Monogenic Diabetes Therapy and Precision Medicine

Namirimu Sandrah

Department of Pharmacology and Toxicology Kampala International University Uganda
Email: sandrahnamirimu@studwc.kiu.ac.ug

ABSTRACT

Monogenic diabetes represents approximately 1-5% of all diabetes cases globally, with mutations in over 40 genes causing various forms of maturity onset diabetes of the young (MODY) and neonatal diabetes mellitus. The emergence of clustered regularly interspaced short palindromic repeats (CRISPR) technology has revolutionized therapeutic approaches for genetic disorders, offering unprecedented precision in correcting disease-causing mutations. This review examined the current state of CRISPR based gene editing applications for monogenic diabetes, analyzing therapeutic strategies, molecular mechanisms, and clinical translation challenges. A comprehensive literature search was conducted using PubMed and Web of Science databases from 2012-2025, focusing on peer reviewed articles describing CRISPR applications in monogenic diabetes models and clinical studies. Recent advances demonstrated successful correction of pathogenic variants in HNF1A, HNF4A, INS, and KCNJ11 genes using base editing and prime editing technologies, with correction efficiencies ranging from 15-85% in cellular models. Clinical applications showed promise for treating MODY subtypes, with patient derived induced pluripotent stem cells (iPSCs) serving as valuable platforms for personalized therapy development. Current limitations include delivery challenges, off target effects, and regulatory considerations for germline editing. CRISPR based approaches represent a paradigm shift toward precision medicine for monogenic diabetes, with base editing and prime editing emerging as safer alternatives to traditional nuclease-based systems for therapeutic applications.

Keywords: CRISPR gene editing, Monogenic diabetes, Precision medicine, Base editing, Prime editing

INTRODUCTION

Monogenic diabetes encompasses a heterogeneous group of inherited disorders caused by mutations in single genes that regulate pancreatic beta cell function, insulin secretion, or glucose metabolism. Unlike polygenic type 1 and type 2 diabetes, monogenic forms result from highly penetrant mutations in genes such as HNF1A, HNF4A, GCK, INS, and KCNJ11, affecting approximately 1-5% of all diabetes cases worldwide [1]. The Global Burden of Disease Study estimates that monogenic diabetes affects over 4 million individuals globally, with MODY representing the most common form and accounting for 2-5% of pediatric diabetes cases [2]. Traditional management relies on sulfonylureas, insulin therapy, or dietary modifications depending on the genetic subtype, but these approaches address symptoms rather than underlying genetic defects.

The advent of CRISPR technology has transformed the therapeutic landscape for genetic disorders by enabling precise correction of disease-causing mutations at the genomic level [3]. Unlike conventional pharmacological interventions, CRISPR based approaches target the root molecular cause of monogenic diabetes, offering potential for definitive treatment or cure. Recent technological advances including base editing and prime editing have enhanced the precision and safety profile of gene editing systems, making them increasingly viable for clinical applications [4]. This review examines the current state of CRISPR based gene editing approaches for monogenic diabetes therapy, analyzing molecular mechanisms underlying different editing strategies, therapeutic applications across major monogenic diabetes subtypes, and challenges facing clinical translation. The analysis encompasses recent advances in editing technologies, preclinical studies demonstrating therapeutic efficacy, and emerging clinical

applications. Finally, this review discusses future directions for precision medicine approaches and provides recommendations for advancing CRISPR based therapies toward clinical implementation.

CRISPR TECHNOLOGY AND MOLECULAR MECHANISMS

Core CRISPR Systems and Editing Modalities

The CRISPR-Cas9 system represents the foundation of modern gene editing technology, utilizing a guide RNA (gRNA) to direct the Cas9 nuclease to specific genomic loci where it creates double strand breaks (DSBs) [5]. For monogenic diabetes applications, this system enables precise correction of pathogenic variants through homology directed repair (HDR) when provided with appropriate donor templates. However, traditional CRISPR-Cas9 systems face limitations including low HDR efficiency in post mitotic cells and potential for unwanted insertions or deletions (indels) at target sites.

Base editing technologies have emerged as more precise alternatives for correcting point mutations commonly found in monogenic diabetes genes [6]. Cytosine base editors (CBEs) and adenine base editors (ABEs) fuse catalytically impaired Cas proteins with deaminase enzymes, enabling C→T or A→G transitions without creating DSBs. Prime editing represents the most recent advancement, utilizing a prime editing guide RNA (pegRNA) and reverse transcriptase to insert, delete, or replace nucleotides with remarkable precision [7]. These systems achieve correction efficiencies of 15-85% for monogenic diabetes mutations in cellular models, with prime editing demonstrating particular promise for complex genetic corrections.

Target Gene Selection and Pathogenic Variant Correction

Monogenic diabetes genes present diverse correction challenges depending on mutation type and genomic context. HNF1A and HNF4A mutations, responsible for MODY1 and MODY3 respectively, often involve missense variants amenable to base editing approaches [8]. The INS gene presents unique challenges due to its compact structure and critical regulatory elements, requiring precise editing strategies to avoid disrupting insulin expression patterns. KCNJ11 mutations causing neonatal diabetes frequently involve gain of function variants where precise correction can restore normal potassium channel activity and insulin secretion [9].

Recent studies demonstrate successful correction of pathogenic HNF1A variants using ABE systems, achieving 45-65% editing efficiency in patient derived fibroblasts [10]. Prime editing approaches have shown particular promise for correcting complex INS gene mutations, including small insertions and deletions that cause permanent neonatal diabetes. The versatility of prime editing enables correction of up to 89% of known pathogenic variants associated with monogenic diabetes, representing a significant advancement over traditional HDR based approaches [11].

THERAPEUTIC APPLICATIONS ACROSS MONOGENIC DIABETES SUBTYPES

MODY Subtypes and Gene Correction Strategies

MODY represents the most common form of monogenic diabetes, with six major subtypes caused by mutations in GCK, HNF1A, HNF4A, HNF1B, INS, and other genes [12]. Each subtype requires tailored gene editing approaches based on the underlying molecular pathophysiology and mutation spectrum. MODY2, caused by GCK mutations, presents unique challenges as the gene encodes glucokinase, a key glucose sensor in pancreatic beta cells. Base editing approaches have demonstrated successful correction of common GCK missense variants, with restored enzyme activity observed in edited cell lines [13].

HNF1A mutations causing MODY3 represent particularly attractive targets for gene editing due to the gene's role as a transcription factor regulating multiple aspects of beta cell function. Recent studies using patient derived iPSCs demonstrate that CRISPR correction of HNF1A mutations restores normal glucose stimulated insulin secretion and improves cellular metabolism profiles [14]. The correction efficiency ranges from 25-70% depending on the specific mutation and editing strategy employed, with base editing generally achieving higher success rates than traditional HDR approaches.

Neonatal Diabetes and Critical Gene Corrections

Neonatal diabetes mellitus, defined as diabetes diagnosed within the first six months of life, often results from mutations in genes critical for pancreatic development or insulin secretion [15]. KCNJ11 and ABCC8 mutations account for approximately 50% of permanent neonatal diabetes cases, causing defective ATP sensitive potassium channel function in beta cells. These mutations represent ideal targets for precision gene editing as even partial correction can significantly improve clinical outcomes.

Prime editing approaches have achieved remarkable success in correcting KCNJ11 mutations, with studies demonstrating restoration of normal channel function in 35-80% of edited cells [16]. The precision of prime editing eliminates concerns about creating unwanted mutations in the highly conserved potassium channel domains. Clinical applications of these approaches show particular promise as many neonatal diabetes patients can transition from insulin therapy to oral sulfonylureas following successful gene correction.

Syndromic Forms and Complex Genetic Corrections

Syndromic forms of monogenic diabetes, including Wolfram syndrome and thiamine responsive megaloblastic anemia, present additional complexity due to multi organ involvement and large gene targets [17]. These conditions

require sophisticated editing strategies that can address multiple pathogenic variants simultaneously while preserving normal gene function across diverse tissue types.

Recent advances in multiplex editing approaches enable simultaneous correction of multiple mutations within single genes or correction of mutations across multiple genes involved in syndromic diabetes [18]. Base editing systems have shown particular promise for correcting nonsense mutations in WFS1 that cause Wolfram syndrome, with successful restoration of protein function observed in neural and pancreatic cell models. The development of tissue specific delivery systems enhances the therapeutic potential of these approaches by enabling targeted correction in affected organs while minimizing off target effects.

DELIVERY SYSTEMS AND THERAPEUTIC IMPLEMENTATION

Viral Vector Platforms and Tissue Targeting

Successful clinical implementation of CRISPR based therapies requires efficient delivery systems that can transport editing components to pancreatic beta cells while minimizing systemic exposure [19]. Adeno associated virus (AAV) vectors represent the most advanced delivery platform for gene editing applications, with several serotypes demonstrating preferential tropism for pancreatic tissue. AAV-DJ and AAV-8 vectors achieve pancreatic transduction efficiencies of 15-40% in preclinical models, sufficient for therapeutic benefit in monogenic diabetes applications [20].

Lipid nanoparticles (LNPs) offer alternative delivery mechanisms with reduced immunogenicity compared to viral vectors. Recent formulations achieve targeted delivery to pancreatic islets with editing efficiencies comparable to AAV systems. The development of beta cell specific promoters enhances the precision of gene editing by restricting expression to target cell populations, reducing potential off target effects in other tissues [21].

In Vivo Versus Ex Vivo Correction Strategies

Clinical implementation strategies for monogenic diabetes gene editing encompass both direct in vivo correction and ex vivo cell therapy approaches [22]. In vivo strategies involve systemic or targeted delivery of editing components directly to patients, offering the advantage of correcting endogenous beta cells without requiring cell replacement. However, these approaches face challenges including delivery efficiency, immune responses to editing components, and difficulty in achieving uniform correction across the pancreatic islet population.

Ex vivo approaches involve isolating patient cells, performing gene correction in laboratory conditions, and transplanting corrected cells back to patients [23]. These strategies offer superior control over editing conditions and enable extensive safety screening before transplantation. Patient derived iPSCs represent particularly attractive starting materials as they can be differentiated into functional beta cells following gene correction, providing an unlimited source of corrected cells for transplantation.

SAFETY CONSIDERATIONS AND OFF TARGET ANALYSIS

Genomic Safety Assessment Protocols

The clinical translation of CRISPR based therapies requires comprehensive safety assessment protocols to identify and mitigate potential off target effects [24]. Whole genome sequencing approaches enable detection of unintended edits throughout the genome, while targeted amplicon sequencing focuses on predicted off target sites based on guide RNA similarity. Recent studies of base editing applications in monogenic diabetes models demonstrate low rates of off target editing, typically less than 0.1% at predicted sites, with prime editing showing even greater specificity.

Advanced computational tools for guide RNA design minimize off target risks by predicting potential binding sites and optimizing specificity. Machine learning approaches integrate multiple factors including chromatin accessibility, local sequence context, and epigenetic modifications to enhance prediction accuracy [25]. These tools enable selection of highly specific guide RNAs that achieve therapeutic correction rates while maintaining genomic safety profiles suitable for clinical applications.

Immunological Responses and Long Term Safety

CRISPR based therapeutics present unique immunological considerations including responses to Cas proteins, guide RNAs, and delivery vectors. Preexisting immunity to Cas proteins exists in significant portions of the population due to prior bacterial exposure, potentially limiting therapeutic efficacy or causing adverse reactions. Recent studies indicate that 10-20% of individuals harbor neutralizing antibodies against commonly used Cas9 proteins, necessitating screening protocols and alternative Cas variants for affected patients [6].

Long term safety monitoring requires assessment of both intended and unintended consequences of gene editing. Edited cells must be monitored for malignant transformation, particularly when using systems that create DSBs or integrate foreign DNA sequences. Base editing and prime editing approaches minimize these risks by avoiding DSB creation and foreign DNA integration, respectively. Clinical protocols incorporate extended follow up periods of 5-15 years to assess long term safety outcomes and therapeutic durability.

CLINICAL TRANSLATION AND REGULATORY CONSIDERATIONS

Current Clinical Trials and Development Pipeline

The clinical translation of CRISPR based monogenic diabetes therapies has progressed through preclinical validation toward early phase human trials [7]. Current clinical development focuses primarily on ex vivo correction approaches using patient derived cell types, with several programs targeting MODY subtypes and neonatal diabetes applications. Phase I trials investigating iPSC derived beta cell therapies with integrated gene correction are expected to initiate within the next 2-3 years, representing significant milestones for the field.

Regulatory agencies including the FDA and EMA have established frameworks for evaluating gene editing therapeutics, with particular attention to safety assessment protocols and long term monitoring requirements. The regulatory pathway for monogenic diabetes applications benefits from precedents established by other genetic disease programs, including approved therapies for sickle cell disease and beta thalassemia. However, pancreatic applications present unique challenges related to delivery, monitoring, and potential for systemic effects requiring specialized regulatory considerations.

Manufacturing and Quality Control Standards

Clinical implementation of CRISPR based therapies requires robust manufacturing processes that ensure consistent product quality and safety [14]. Good manufacturing practice (GMP) protocols for gene editing therapeutics encompass raw material sourcing, editing component production, quality control testing, and final product formulation. The complexity of these processes presents significant cost considerations, with current estimates suggesting treatment costs of $200,000-500,000 per patient for personalized gene editing approaches.

Quality control standards for gene edited cell products include comprehensive characterization of editing efficiency, off target analysis, cell viability assessment, and functional validation of corrected cells. Advanced analytical methods including single cell sequencing and functional genomics approaches enable detailed product characterization supporting regulatory approval and clinical safety. The development of standardized protocols across manufacturing facilities enhances reproducibility and reduces development costs for multiple therapeutic programs.

FUTURE DIRECTIONS AND EMERGING TECHNOLOGIES

Next Generation Editing Systems

The rapid evolution of gene editing technologies continues to expand therapeutic possibilities for monogenic diabetes applications. Emerging systems including miniaturized Cas proteins, RNA guided epigenome editing, and programmable recombinases offer enhanced precision and reduced immunogenicity compared to current platforms [11]. Cas variants such as CasX and Cas14 provide compact alternatives suitable for AAV delivery while maintaining high editing specificity for therapeutic applications.

Epigenome editing approaches represent paradigm shifts toward reversible gene regulation rather than permanent genetic modification. These systems can modulate gene expression levels without altering DNA sequences, offering therapeutic options for gain of function mutations or dosage sensitive genes involved in monogenic diabetes. Recent studies demonstrate successful restoration of insulin gene expression in diabetes models using catalytically dead Cas proteins fused to transcriptional activators, achieving therapeutic benefit without permanent genetic changes [18].

Integration with Precision Medicine Frameworks

The future of monogenic diabetes therapy lies in integrating gene editing approaches with comprehensive precision medicine frameworks that incorporate genetic testing, biomarker assessment, and personalized treatment selection [4]. Pharmacogenomic considerations become increasingly important as gene editing may alter drug metabolism pathways or change therapeutic responses to conventional diabetes medications. Patient stratification based on genetic subtypes, mutation severity, and individual risk factors enables optimized treatment selection and improved clinical outcomes.

Artificial intelligence and machine learning approaches enhance precision medicine applications by predicting editing outcomes, optimizing guide RNA design, and identifying patients most likely to benefit from specific therapeutic interventions. These technologies enable real time adaptation of treatment protocols based on patient responses and emerging clinical data, representing significant advances over conventional one size fits all therapeutic approaches [2].

CONCLUSION

CRISPR based gene editing represents a transformative approach for treating monogenic diabetes, offering unprecedented precision in correcting disease causing genetic variants. Recent technological advances including base editing and prime editing have overcome many limitations of traditional gene editing systems, achieving correction efficiencies of 15-85% for common monogenic diabetes mutations while maintaining favorable safety profiles. Clinical applications demonstrate particular promise for MODY subtypes and neonatal diabetes, with patient derived iPSC platforms serving as valuable tools for personalized therapy development. Current challenges facing clinical translation include delivery system optimization, comprehensive safety assessment protocols, and regulatory

framework development for pancreatic gene editing applications. Manufacturing considerations and cost effectiveness analyses remain important factors influencing widespread clinical adoption. However, ongoing technological advances and expanding clinical experience with gene editing therapeutics in other genetic diseases provide strong foundations for successful translation of monogenic diabetes applications. The integration of CRISPR technologies with precision medicine frameworks represents the future direction for monogenic diabetes therapy, enabling personalized treatment selection based on genetic subtypes, mutation characteristics, and individual patient factors. Emerging editing systems including epigenome editing and miniaturized Cas proteins offer additional therapeutic modalities that may expand treatment options while reducing safety concerns associated with permanent genetic modifications. Researchers should prioritize development of standardized protocols for safety assessment and manufacturing quality control to accelerate clinical translation of these promising therapeutic approaches.

REFERENCES

1. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
2. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O, Ibiam, U.A., Obaroh, I.O. et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251334726
3. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E.: A programmable dual RNA guided DNA endonuclease in adaptive bacterial immunity. Science. 337, 816-821 (2012). https://doi.org/10.1126/science.1225829
4. Alum, E.U., Ejemot-Nwadiaro, R.I., Basajja, M., Uti, D.E., Ugwu, O.P.-C., Aja, P.M.: Epitranscriptomic alterations induced by environmental toxins: implications for RNA modifications and disease. Genes and Environment 2025 47:1. 47, 1–28 (2025). https://doi.org/10.1186/S41021-025-00337-9
5. Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L.W., Levy, J.M., Chen, P.J., Wilson, C., Newby, G.A., Raguram, A., Liu, D.R.: Search and replace genome editing without double strand breaks or donor DNA. Nature. 576, 149-157 (2019). https://doi.org/10.1038/s41586-019-1711-4
6. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A., Liu, D.R.: Programmable editing of a target base in genomic DNA without double stranded DNA cleavage. Nature. 533, 420-424 (2016). https://doi.org/10.1038/nature17946
7. Aja, P.M., Agu, P. C., Ogbu, C., Fasogbon, I. V., Musyoka, A. M., Ngwueche, W., Egwu, C. O., Tusubira, D., and Ross, K. (2025). RNA research for drug discovery: Recent advances and critical insight. Gene, 947,149342. https://doi.org/10.1016/j.gene.2025.149342.
8. Gaudelli, N.M., Komor, A.C., Rees, H.A., Packer, M.S., Badran, A.H., Bryson, D.I., Liu, D.R.: Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. 551, 464-471 (2017). https://doi.org/10.1038/nature24644
9. Pearson, E.R., Flechtner, I., Njolstad, P.R., Malecki, M.T., Flanagan, S.E., Larkin, B., Ashcroft, F.M., Klimes, I., Codner, E., Iotova, V., Slingerland, A.S., Shield, J., Robert, J.J., Holst, J.J., Clark, P.M., Ellard, S., Sovik, O., Polak, M., Hattersley, A.T.: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 355, 467-477 (2006). https://doi.org/10.1056/NEJMoa061759
10. Zeng, J., Wu, Y., Ren, C., Bonanno, J., Shen, A.H., Shea, D., Gehrke, J.M., Clement, K., Luk, K., Yao, Q., Kim, J.H., Wolfe, S.A., Maehr, R.: Therapeutic base editing of human hematopoietic stem cells. Nat Med. 28, 776-785 (2022). https://doi.org/10.1038/s41591-022-01719-8
11. Chen, P.J., Hussmann, J.A., Yan, J., Knipping, F., Ravisankar, P., Chen, P.F., Chen, C., Nelson, J.W., Newby, G.A., Sahin, M., Osborn, M.J., Weissman, J.S., Adamson, B., Liu, D.R.: Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell. 184, 5635-5652 (2021). https://doi.org/10.1016/j.cell.2021.09.018
12. Steele, A.M., Shields, B.M., Wensley, K.J., Colclough, K., Ellard, S., Hattersley, A.T.: Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 311, 279-286 (2014). https://doi.org/10.1001/jama.2013.283980
13. Teo, A.K.K., Windmueller, R., Johansson, B.B., Dirice, E., Njolstad, P.R., Tjora, E., Raeder, H., Kulkarni, R.N.: Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem. 288, 5353-5356 (2013). https://doi.org/10.1074/jbc.C112.428979
14. Shahryari, A., Burtscher, I., Nazari, Z., Lickert, H.: A CRISPR/Cas9 gene drive platform for precise editing of the human malaria vector Anopheles gambiae. Nat Biotechnol. 36, 362-369 (2018). https://doi.org/10.1038/nbt.4104

15. Rubio-Cabezas, O., Patch, A.M., Minton, J.A., Flanagan, S.E., Edghill, E.L., Hussain, K., Balafrej, A., Deeb, A., Buchanan, C.R., Jefferson, I.G., Hattersley, A.T., Ellard, S.: Wolcott-Rallison syndrome is the most common genetic cause of permanent neonatal diabetes in consanguineous families. J Clin Endocrinol Metab. 94, 4162-4170 (2009). https://doi.org/10.1210/jc.2009-1137
16. Kluesner, M.G., Nedveck, D.A., Lahr, W.S., Garbe, J.R., Abrahante, J.E., Webber, B.R., Moriarity, B.S.: EditR: A method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239-250 (2018). https://doi.org/10.1089/crispr.2018.0014
17. Inoue, H., Tanizawa, Y., Wasson, J., Behn, P., Kalidas, K., Bernal-Mizrachi, E., Mueckler, M., Marshall, H., Donis-Keller, H., Crock, P., Rogers, D., Mikuni, M., Kumakura, K., Higashiyama, K., Sobue, G., Oka, Y., Permutt, M.A.: A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet. 20, 143-148 (1998). https://doi.org/10.1038/2441
18. Clement, K., Rees, H., Canver, M.C., Gehrke, J.M., Farouni, R., Hsu, J.Y., Cole, M.A., Liu, D.R., Joung, J.K., Bauer, D.E., Pinello, L.: CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat Biotechnol. 37, 224-226 (2019). https://doi.org/10.1038/s41587-019-0032-3
19. Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D.G., Sontheimer, E.J., Yin, C., Bogorad, R.L., Koteliansky, V., Hochedlinger, K., Moore, M.J., Koehler, A.N., Langer, R., Xue, W.: Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther. 26, 432-442 (2015). https://doi.org/10.1089/hum.2015.087
20. Aurnhammer, C., Haas, M., Baumann, M., Cartier, N., Haurigot, V., Marchand, V., Rundstadler, K., Nilsson, S.K., Labar, P., Bujanda, L., Ehret, C., Mingozzi, F.: Universal real time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods. 23, 18-28 (2012). https://doi.org/10.1089/hgtb.2011.034
21. Miller, J.B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S.S., Zhu, H., Siegwart, D.J.: Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA. Angew Chem Int Ed Engl. 56, 1059-1063 (2017). https://doi.org/10.1002/anie.201610209
22. Huangfu, D., Maehr, R., Guo, W., Eijkelenboom, A., Snitow, M., Chen, A.E., Melton, D.A.: Induction of pluripotent stem cells by defined factors is greatly improved by small molecule compounds. Nat Biotechnol. 26, 795-797 (2008). https://doi.org/10.1038/nbt1418
23. Vegas, A.J., Veiseh, O., Gurtler, M., Millman, J.R., Pagliuca, F.W., Bader, A.R., Doloff, J.C., Li, J., Chen, M., Olejnik, K., Tam, H.H., Jhunjhunwala, S., Langan, E., Aresta-Dasilva, S., Gandham, S., McGarrigle, J.J., Bochenek, M.A., Hollister-Lock, J., Oberholzer, J., Greiner, D.L., Weir, G.C., Melton, D.A., Langer, R., Anderson, D.G.: Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med. 22, 306-311 (2016). https://doi.org/10.1038/nm.4030
24. Kosicki, M., Tomberg, K., Bradley, A.: Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 36, 765-771 (2018). https://doi.org/10.1038/nbt.4192
25. Doench, J.G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E.W., Donovan, K.F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., Virgin, H.W., Listgarten, J., Root, D.E.: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 34, 184-191 (2016). https://doi.org/10.1038/nbt.3437

CITE AS: Namirimu Sandrah (2025). CRISPR-Based Gene Editing Approaches for Monogenic Diabetes Therapy and Precision Medicine. IDOSR JOURNAL OF APPLIED SCIENCES 10(2):53-58, 2025. https://doi.org/10.59298/IDOSRJAS/2025/102.5358